Study on myelin injury of AD mice treated with Shenzhiling oral liquid in the PI3K/Akt–mTOR pathway

Shenzhiling oral liquid (SZL) is a Traditional Chinese Medicine (TCM) compound to be approved by the China Food and Drug Administration (CFDA) (Z20120010) for the treatment of mild-to-moderate Alzheimer’s disease (AD). However, its mechanism in early AD is not clear. We studied its mechanism in prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yahan, Chen, Fang, Wang, Pengwen, Mana, Lulu, Sheng, Ning, Huang, Shuaiyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262987/
https://www.ncbi.nlm.nih.gov/pubmed/32462951
http://dx.doi.org/10.1177/2058738420923907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262987/
https://www.ncbi.nlm.nih.gov/pubmed/32462951
http://dx.doi.org/10.1177/2058738420923907

Ejemplares similares